Published in Gastroenterology on January 25, 2010
Clinical Trial of Pentoxifylline in Patient With Cirrhosis (PENTOCIR) | NCT00162552
New consensus definition of acute kidney injury accurately predicts 30-day mortality in patients with cirrhosis and infection. Gastroenterology (2013) 1.35
Current status of novel antifibrotic therapies in patients with chronic liver disease. Therap Adv Gastroenterol (2011) 1.34
Alcoholic hepatitis: current challenges and future directions. Clin Gastroenterol Hepatol (2013) 1.25
Alcoholic liver disease. World J Hepatol (2012) 1.16
Pharmacological agents for NASH. Nat Rev Gastroenterol Hepatol (2013) 1.15
Alcoholic hepatitis 2010: a clinician's guide to diagnosis and therapy. World J Gastroenterol (2010) 1.13
Kidneys in chronic liver diseases. World J Gastroenterol (2012) 1.10
Advances in alcoholic liver disease. Curr Gastroenterol Rep (2011) 0.98
Risk factors and outcome of bacterial infections in cirrhosis. World J Gastroenterol (2014) 0.95
Recent advances in our understanding of hepatorenal syndrome. Nat Rev Gastroenterol Hepatol (2012) 0.94
Austrian consensus on the definition and treatment of portal hypertension and its complications (Billroth II). Wien Klin Wochenschr (2013) 0.93
Adenosine modulates Toll-like receptor function: basic mechanisms and translational opportunities. Expert Rev Anti Infect Ther (2011) 0.90
Sinusoidal communication in liver fibrosis and regeneration. J Hepatol (2016) 0.88
Ethanol and liver: recent insights into the mechanisms of ethanol-induced fatty liver. World J Gastroenterol (2014) 0.87
Bench-to-beside review: acute-on-chronic liver failure - linking the gut, liver and systemic circulation. Crit Care (2011) 0.87
Pentoxifylline aggravates fatty liver in obese and diabetic ob/ob mice by increasing intestinal glucose absorption and activating hepatic lipogenesis. Br J Pharmacol (2012) 0.83
Acute-on-chronic liver failure: terminology, mechanisms and management. Nat Rev Gastroenterol Hepatol (2016) 0.82
Management practices of hepatitis C virus infected alcoholic hepatitis patients: A survey of physicians. World J Gastrointest Pharmacol Ther (2013) 0.81
Current Management of Alcoholic Hepatitis and Future Therapies. J Clin Transl Hepatol (2016) 0.80
Hepatoprotective Effects of Chinese Medicinal Herbs: A Focus on Anti-Inflammatory and Anti-Oxidative Activities. Int J Mol Sci (2016) 0.80
Pathogenesis and management of alcoholic liver cirrhosis: a review. Hepat Med (2011) 0.78
Pharmacotherapy of acute alcoholic hepatitis in clinical practice. World J Gastroenterol (2014) 0.78
Hepatorenal syndrome: outcome of response to therapy and predictors of survival. Gastroenterol Res Pract (2015) 0.78
Diagnosis and Treatment of Alcoholic Hepatitis: A Systematic Review. Alcohol Clin Exp Res (2016) 0.77
Managing alcoholic liver disease. Clin Mol Hepatol (2015) 0.77
Alcoholic Hepatitis: Steroids vs. Pentoxifylline. Curr Hepat Rep (2013) 0.76
Role of pentoxifylline and sparfloxacin in prophylaxis of spontaneous bacterial peritonitis in cirrhotic patients. ISRN Gastroenterol (2014) 0.75
When to use antibiotics in the cirrhotic patient? The evidence base. Ann Gastroenterol (2013) 0.75
Liver: Can pentoxifylline secure its place in liver therapeutics? Nat Rev Gastroenterol Hepatol (2010) 0.75
[Management of severe alcoholic hepatitis]. Wien Med Wochenschr (2013) 0.75
Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology (2010) 8.11
Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology (2005) 7.03
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology (2010) 6.14
Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology (2013) 5.88
Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology (2009) 5.87
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol (2013) 5.64
Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology (2002) 5.48
Viral hepatitis B. Lancet (2003) 4.86
Diagnostic accuracy of the Multistix 8 SG reagent strip in diagnosis of spontaneous bacterial peritonitis. Hepatology (2007) 3.75
Acute-on chronic liver failure. J Hepatol (2012) 3.74
Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem (2004) 3.45
A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med (2006) 3.21
Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology (2008) 3.15
The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology (2003) 3.00
Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study. Hepatology (2010) 2.82
Liver fibrosis in viral hepatitis: noninvasive assessment with acoustic radiation force impulse imaging versus transient elastography. Radiology (2009) 2.79
A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int (2011) 2.77
Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis. Gut (2011) 2.65
Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology (2013) 2.62
Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: a cross-over study. J Hepatol (2011) 2.59
Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients. AIDS (2003) 2.58
Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study. Hepatology (2003) 2.57
Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. N Engl J Med (2011) 2.44
Portal cavernoma-associated cholangiopathy: a clinical and MR cholangiography coupled with MR portography imaging study. Hepatology (2003) 2.43
Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J Hepatol (2009) 2.39
Severe sepsis in cirrhosis. Hepatology (2009) 2.33
Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis. Liver Int (2010) 2.32
Noninvasive prediction of fibrosis in patients with chronic hepatitis C. Hepatology (2003) 2.23
The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood (2008) 2.21
Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol (2003) 2.19
Neurological improvement during bioartificial liver sessions in patients with acute liver failure awaiting transplantation. Transplantation (2002) 2.19
Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol (2004) 2.19
Immediate listing for liver transplantation versus standard care for Child-Pugh stage B alcoholic cirrhosis: a randomized trial. Ann Intern Med (2009) 2.16
Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology (2010) 2.13
Pulmonary complications after elective liver transplantation-incidence, risk factors, and outcome. Transplantation (2012) 2.11
IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. Hepatology (2011) 2.11
The evaluation of renal function and disease in patients with cirrhosis. J Hepatol (2010) 2.10
Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Hepatology (2009) 2.10
Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial. Hepatology (2013) 2.08
A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology (2005) 2.08
Effect of prolonged interferon therapy on the outcome of hepatitis C virus-related cirrhosis: a randomized trial. Clin Gastroenterol Hepatol (2007) 2.08
Progression of liver fibrosis in women infected with hepatitis C: long-term benefit of estrogen exposure. Hepatology (2004) 2.08
Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology (2002) 2.06
Autophagy in liver diseases. J Hepatol (2010) 2.06
Anti-tumor necrosis factor-alpha therapy in severe alcoholic hepatitis: are large randomized trials still possible? J Hepatol (2003) 2.04
Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology (2002) 2.02
Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. Gastroenterology (2004) 2.01
Prospective evaluation of the prognostic scores for cirrhotic patients admitted to an intensive care unit. J Hepatol (2011) 1.99
Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology (2012) 1.95
Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European collaborative study. Hepatology (2002) 1.94
Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial. JAMA (2013) 1.94
Cirrhotic patients in the medical intensive care unit: early prognosis and long-term survival. Crit Care Med (2010) 1.94
Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol (2006) 1.86
Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy. Hepatology (2009) 1.84
A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J Hepatol (2013) 1.84
Impact of expanding criteria for resectability of colorectal metastases on short- and long-term outcomes after hepatic resection. Ann Surg (2011) 1.83
Microbial epidemiology and outcome of bloodstream infections in liver transplant recipients: an analysis of 259 episodes. Liver Transpl (2010) 1.81
Diabetes mellitus is an independent prognostic factor for major liver-related outcomes in patients with cirrhosis and chronic hepatitis C. Hepatology (2014) 1.81
A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Clin Chem (2006) 1.78
A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. Gastroenterology (2005) 1.76
The spectrum of renal lesions in patients with cirrhosis: a clinicopathological study. Liver Int (2009) 1.76
Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. Gastroenterology (2011) 1.71
Liver stiffness is an unreliable marker of liver fibrosis in patients with cardiac insufficiency. Hepatology (2008) 1.70
Abnormal plasma microparticles impair vasoconstrictor responses in patients with cirrhosis. Gastroenterology (2012) 1.69
Non-invasive measurement of liver and pancreas fibrosis in patients with cystic fibrosis. J Cyst Fibros (2013) 1.66
Management of critically-ill cirrhotic patients. J Hepatol (2012) 1.65
Both IgA nephropathy and alcoholic cirrhosis feature abnormally glycosylated IgA1 and soluble CD89-IgA and IgG-IgA complexes: common mechanisms for distinct diseases. Kidney Int (2011) 1.64
Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. J Hepatol (2005) 1.63
Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease? Am J Gastroenterol (2006) 1.63
Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: results of a longitudinal study. Hepatology (2015) 1.62
Assessment of adrenal function in cirrhotic patients: salivary cortisol should be preferred. J Hepatol (2010) 1.60
Comparing the public health burden of chronic hepatitis C and HIV infection in France. J Hepatol (2004) 1.57
The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Comp Hepatol (2005) 1.54
Identification of restricted subsets of mature microRNA abnormally expressed in inactive colonic mucosa of patients with inflammatory bowel disease. PLoS One (2010) 1.54
Improved prognosis of septic shock in patients with cirrhosis: a multicenter study*. Crit Care Med (2014) 1.52
Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study. Cancer (2007) 1.51
High-density lipoprotein administration attenuates liver proinflammatory response, restores liver endothelial nitric oxide synthase activity, and lowers portal pressure in cirrhotic rats. Hepatology (2007) 1.50
Prognostic scores for cirrhotic patients admitted to an intensive care unit: which consequences for liver transplantation? Clin Res Hepatol Gastroenterol (2013) 1.50
Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol (2007) 1.49
Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol (2006) 1.47
HCV-GenoFibrotest: a combination of viral, liver and genomic (IL28b, ITPA, UGT1A1) biomarkers for predicting treatment response in patients with chronic hepatitis C. Clin Res Hepatol Gastroenterol (2011) 1.47
Hepatocyte nuclear factor-1 alpha gene inactivation: cosegregation between liver adenomatosis and diabetes phenotypes in two maturity-onset diabetes of the young (MODY)3 families. J Clin Endocrinol Metab (2004) 1.46
Twenty-year protocol liver biopsies: Invasive but useful for the management of liver recipients. J Hepatol (2011) 1.46
Long-term therapy with lamivudine in renal transplant recipients with chronic hepatitis B. Eur J Gastroenterol Hepatol (2004) 1.44
Liver biopsy: the best standard...when everything else fails. J Hepatol (2009) 1.43